Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions.

ABSTRACT: The worldwide prevalence of non-alcoholic steatohepatitis (NASH) is increasing, causing a significant medical burden, but no approved therapeutics are currently available. NASH drug development requires histological analysis of liver biopsies by expert pathologists for trial enrolment and efficacy assessment, which can be hindered by multiple issues including sample heterogeneity, inter-reader and intra-reader variability, and ordinal scoring systems. Consequently, there is a high unmet need for accurate, reproducible, quantitative, and automated methods to assist pathologists with histological analysis to improve the precision around treatment and efficacy assessment. Digital pathology (DP) workflows in combination with artificial intelligence (AI) have been established in other areas of

SUBMITTER: Ratziu V 

PROVIDER: S-EPMC11822446 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature